Berber Piet

2.6k total citations · 1 hit paper
32 papers, 1.8k citations indexed

About

Berber Piet is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Berber Piet has authored 32 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 15 papers in Immunology and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Berber Piet's work include Cancer Immunotherapy and Biomarkers (13 papers), Immunotherapy and Immune Responses (9 papers) and Immune Cell Function and Interaction (8 papers). Berber Piet is often cited by papers focused on Cancer Immunotherapy and Biomarkers (13 papers), Immunotherapy and Immune Responses (9 papers) and Immune Cell Function and Interaction (8 papers). Berber Piet collaborates with scholars based in Netherlands, United States and United Kingdom. Berber Piet's co-authors include Cornelis M. van Drunen, Charlotte P. Peters, Hergen Spits, Natasha K. Crellin, Jenny Mjösberg, Wytske J. Fokkens, Sara Trifari, Tom Cupedo, René A. W. van Lier and René E. Jonkers and has published in prestigious journals such as Journal of Clinical Investigation, Nature Immunology and Clinical Cancer Research.

In The Last Decade

Berber Piet

28 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161

2011 931 citations Jenny Mjösberg, Sara Trifari et al. Nature Immunology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Berber Piet Netherlands	12	1.5k	592	346	340	140	32	1.8k
Masamichi Koike Japan	13	529 0.4×	312 0.5×	782 2.3×	133 0.4×	35 0.3×	20	1.3k
Valentina Querci Italy	13	1.6k 1.1×	99 0.2×	218 0.6×	264 0.8×	161 1.1×	13	1.9k
Achilleas Floudas Ireland	19	679 0.5×	139 0.2×	134 0.4×	227 0.7×	56 0.4×	32	1.3k
Vassilios Lougaris Italy	23	1.3k 0.9×	134 0.2×	74 0.2×	196 0.6×	250 1.8×	92	1.8k
Osamu Saiki Japan	21	788 0.5×	230 0.4×	54 0.2×	233 0.7×	154 1.1×	52	1.4k
Laure Bourdery United States	6	1.6k 1.1×	78 0.1×	89 0.3×	209 0.6×	222 1.6×	7	1.9k
Stephen H. Olsen United States	8	959 0.6×	87 0.1×	101 0.3×	148 0.4×	230 1.6×	17	1.5k
Michael Girschikofsky Austria	15	638 0.4×	447 0.8×	645 1.9×	332 1.0×	223 1.6×	33	2.1k
Jacob Aelion United States	20	1.1k 0.7×	71 0.1×	131 0.4×	139 0.4×	159 1.1×	46	1.8k
Jill Giles‐Komar United States	17	632 0.4×	131 0.2×	232 0.7×	164 0.5×	161 1.1×	30	1.3k

Countries citing papers authored by Berber Piet

Since Specialization

Citations

This map shows the geographic impact of Berber Piet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Berber Piet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Berber Piet more than expected).

Fields of papers citing papers by Berber Piet

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Berber Piet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Berber Piet. The network helps show where Berber Piet may publish in the future.

Co-authorship network of co-authors of Berber Piet

This figure shows the co-authorship network connecting the top 25 collaborators of Berber Piet. A scholar is included among the top collaborators of Berber Piet based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Berber Piet. Berber Piet is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Piet, Berber, et al.. (2025). Very Early Health Technology Assessment for Potential Predictive Biomarkers in the Treatment of Advanced Non-Small Cell Lung Cancer. PharmacoEconomics - Open. 9(3). 471–485.

Piet, Berber, et al.. (2025). Ex vivo pembrolizumab pharmacology for personalized PD-1 inhibitor therapy reveals a critical gap between receptor occupancy and T cell functionality. International Immunopharmacology. 157. 114754–114754.

Zeverijn, Laurien J., Birgit S. Geurts, Gijs F. de Wit, et al.. (2024). Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non–Small Cell Lung Cancer—Results from the Drug Rediscovery Protocol. Clinical Cancer Research. 30(23). 5323–5332. 1 indexed citations

Hendriks, Lizza, Kristien Winckers, Yvonne Henskens, et al.. (2024). Proactive monitoring of drug–drug interactions between direct oral anticoagulants and small-molecule inhibitors in patients with non-small cell lung cancer. British Journal of Cancer. 131(3). 481–490. 1 indexed citations

Perera, Tim, Peter de Bruijn, Rachel Galot, et al.. (2024). 143 (PB131): Preliminary Safety and Pharmacokinetics of the MET-TKI DO-2 in Patients with Advanced Solid Tumors Harboring MET Aberrations: A Phase I Study. European Journal of Cancer. 211. 114665–114665. 1 indexed citations

Piet, Berber, et al.. (2024). Development and validation of an ultra‐performance liquid chromatography–tandem mass spectrometry method to quantify the small molecule inhibitors adagrasib, alectinib, brigatinib, capmatinib, crizotinib, lorlatinib, selpercatinib, and sotorasib in human plasma. Biomedical Chromatography. 38(10). 1 indexed citations

Verkerk, Karin, Laurien J. Zeverijn, Birgit S. Geurts, et al.. (2023). 1392P Safety and efficacy of crizotinib in MET mutated (METmut) advanced non-small cell lung Cancer (aNSCLC): Results from the Drug Rediscovery Protocol (DRUP). Annals of Oncology. 34. S797–S798. 3 indexed citations

Verrijp, Kiek, Johannes Textor, Georgina Flórez‐Grau, et al.. (2023). Detection of dendritic cell subsets in the tumor microenvironment by multiplex immunohistochemistry. European Journal of Immunology. 54(1). e2350616–e2350616. 5 indexed citations

Koenen, Hans J. P. M., Ruben L. Smeets, Berber Piet, et al.. (2023). Evidence‐based rationale for low dose nivolumab in critically ill patients with sepsis‐induced immunosuppression. Clinical and Translational Science. 16(6). 978–986. 10 indexed citations

10.

Piet, Berber, et al.. (2023). Prognostic Value of Nivolumab Clearance in Non-Small Cell Lung Cancer Patients for Survival Early in Treatment. Clinical Pharmacokinetics. 62(12). 1749–1754. 1 indexed citations

11.

Piet, Berber, et al.. (2023). Integrating treatment cost reduction strategies and biomarker research to reduce costs and personalize expensive treatments: an example of a self-funding trial in non-small cell lung cancer. Frontiers in Pharmacology. 14. 1274532–1274532. 6 indexed citations

12.

Heine, Rob ter, Michel M. van den Heuvel, Berber Piet, et al.. (2023). A Systematic Evaluation of Cost-Saving Dosing Regimens for Therapeutic Antibodies and Antibody-Drug Conjugates for the Treatment of Lung Cancer. Targeted Oncology. 18(3). 441–450. 8 indexed citations

13.

Woude, Lieke L. van der, Mark A.J. Gorris, Inge M. N. Wortel, et al.. (2022). Tumor microenvironment shows an immunological abscopal effect in patients with NSCLC treated with pembrolizumab-radiotherapy combination. Journal for ImmunoTherapy of Cancer. 10(10). e005248–e005248. 28 indexed citations

14.

Boosman, René J., Jacobus A. Burgers, Alwin D. R. Huitema, et al.. (2022). Renal function-based versus standard dosing of pemetrexed: a randomized controlled trial. Cancer Chemotherapy and Pharmacology. 91(1). 33–42.

15.

Piet, Berber, Michel M. van den Heuvel, Catia Marzolini, et al.. (2022). Practical recommendations to combine small-molecule inhibitors and direct oral anticoagulants in patients with nonsmall cell lung cancer. European Respiratory Review. 31(164). 220004–220004. 11 indexed citations

16.

Wekken, Anthonie J. van der, et al.. (2021). Pharmacokinetically‐guided dosing to improve the efficacy of brigatinib in non‐small cell lung cancer patients. British Journal of Clinical Pharmacology. 88(4). 1930–1934. 2 indexed citations

17.

Flórez‐Grau, Georgina, et al.. (2021). Recent Advances and Future Perspective of DC-Based Therapy in NSCLC. Frontiers in Immunology. 12. 704776–704776. 14 indexed citations

18.

Westdorp, Harm, Mark A.J. Gorris, Frank Hoentjen, et al.. (2021). Mechanisms of Immune Checkpoint Inhibitor-Mediated Colitis. Frontiers in Immunology. 12. 768957–768957. 31 indexed citations

19.

Oja, Anna E., Berber Piet, Hans Blaauwgeers, et al.. (2018). Functional Heterogeneity of CD4+ Tumor-Infiltrating Lymphocytes With a Resident Memory Phenotype in NSCLC. Frontiers in Immunology. 9. 2654–2654. 93 indexed citations

20.

Mjösberg, Jenny, Sara Trifari, Natasha K. Crellin, et al.. (2011). Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161. Nature Immunology. 12(11). 1055–1062. 931 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact